Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

External medicament for treating infant hemangioma and preparation method thereof

A technology for infantile hemangioma and topical drugs, applied in the field of medicine, can solve problems such as not recommended for use in children, unclear side effects of drugs, and limitations in clinical application

Inactive Publication Date: 2012-07-18
SHANDONG PROVINCIAL HOSPITAL
View PDF1 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

According to clinical observations, oral propranolol has a significant effect, but there are many side effects, such as blood pressure and heart rate drop, blood sugar change, milk overflow, diarrhea, mental symptoms, etc., and it needs to be treated under hospital supervision, which brings a lot of inconvenience to family life. Because the side effects of this drug in infants and young children are not yet clear, it is not recommended for children under 3 months
In short, the above treatment methods all have defects in varying degrees, which greatly restrict their clinical application.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • External medicament for treating infant hemangioma and preparation method thereof
  • External medicament for treating infant hemangioma and preparation method thereof
  • External medicament for treating infant hemangioma and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Ratio: 10 parts of propranolol, 50 parts of stearic acid, 40 parts of glyceryl monostearate, 50 parts of white petrolatum, 5 parts of laurozone, 5 parts of oleic acid, 10 parts of Tween-80, 70 parts of glycerin Parts, 500 parts of deionized water, 1 part of ethyl paraben.

[0033] Its preparation method is:

[0034] According to the solubility properties of the pharmaceutical composition, it is divided into the following two parts

[0035] Oily components: stearic acid, glyceryl monostearate, white petrolatum, laurocapram, oleic acid

[0036] Water-soluble components: Tween-80, glycerin, deionized water, propranolol, ethyl paraben

[0037] Accurately weigh the oily component and the water-soluble component respectively, heat them separately and keep them at 75°C±2°C; then slowly add the oily component into the water-soluble component, and keep stirring in the same direction until the emulsification is complete and condense into a paste.

[0038] Quality Control

[...

Embodiment 2

[0042] Proportion: 50 parts of propranolol, 220 parts of stearic acid, 150 parts of glyceryl monostearate, 200 parts of white petrolatum, 40 parts of laurozone, 40 parts of oleic acid, 60 parts of Tween-80, 300 parts of glycerin Parts, 1000 parts of deionized water, 10 parts of ethyl paraben.

[0043] Its preparation method is:

[0044] According to the nature of the pharmaceutical composition, it is divided into the following two parts

[0045]Oily components: stearic acid, glyceryl monostearate, white petrolatum, laurocapram, oleic acid

[0046] Water-soluble components: Tween-80, glycerin, deionized water, propranolol, ethyl paraben

[0047] Accurately weigh the oily component and the water-soluble component respectively, heat them separately and keep them at 75°C±2°C; then slowly add the oily component into the water-soluble component, and keep stirring in the same direction until the emulsification is complete and condense into a paste.

Embodiment 3

[0049] Proportion: 20 parts of propranolol, 100 parts of stearic acid, 80 parts of glyceryl monostearate, 100 parts of white petrolatum, 15 parts of laurozone, 15 parts of oleic acid, 30 parts of Tween-80, 120 parts of glycerin Parts, 700 parts of deionized water, 3 parts of ethyl paraben.

[0050] Its preparation method is:

[0051] According to the nature of the pharmaceutical composition, it is divided into the following two parts

[0052] Oily components: stearic acid, glyceryl monostearate, white petrolatum, laurocapram, oleic acid

[0053] Water-soluble components: Tween-80, glycerin, deionized water, propranolol, ethyl paraben

[0054] Accurately weigh the oily component and the water-soluble component respectively, heat them separately and keep them at 75°C±2°C; then slowly add the oily component into the water-soluble component, and keep stirring in the same direction until the emulsification is complete and condense into a paste.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an external medicament for treating infant hemangioma and a preparation method thereof, which belong to the technical field of medicine. The external medicament comprises the following components: propranolol, stearic acid, glycerin monostearate, white Vaseline, azone, oleic acid, Tween-80, glycerol, deionized water and ethylparaben. The method comprises the following steps of: accurately weighing a certain amount of greasy component and a certain amount of water-soluble component respectively, and heating and preserving heat respectively at 75+ / -2 DEG C; and slowly adding the greasy component into the water-soluble component, and continuously stirring along the same direction till the mixture is fully emulsified and is condensed into paste. The external medicament is safe and reliable. As proved by clinical experiments, after the external medicament is uniformly smeared onto the surface of a tumor body, the tumor body is faded remarkably 2-3 months later, 59 percent of infant patients can be cured 5-7 months later, 33 percent of tumor bodies are faded remarkably, and the total yield is 92 percent.

Description

technical field [0001] The invention relates to a pharmaceutical composition and a preparation method thereof, in particular to a medicine for external use for treating infantile hemangioma and a preparation method thereof, belonging to the technical field of medicine. Background technique [0002] Infantile hemangioma is the most common benign tumor in infancy, with an incidence rate of 1% to 2% in children, and the incidence rate of females is higher than that of males, with a ratio of 3:1. The pathological process of the lesions has the characteristics of spontaneous regression, and most of them appear at birth or within 1 month after birth. In the first 6 months, the growth rate is very rapid, and then the growth rate gradually slows down. Since the child is about 1 year old, it begins to enter In the extinction stage, most of the extinction is completed at the age of 7 to 8 years. Although most hemangiomas show an obvious pathological process of spontaneous regression,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/138A61K9/06A61K47/44A61P35/00
Inventor 霍然徐广琪傅洪滨王爱武吕仁荣薛文君牛静静
Owner SHANDONG PROVINCIAL HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com